Incompatibility of the short-acting benzodiazepine remimazolam with common perioperative medication.
Coadministration
Incompatibility
Interaction
Precipitation
Remimazolam
Simulated y-site administration
Journal
BMC anesthesiology
ISSN: 1471-2253
Titre abrégé: BMC Anesthesiol
Pays: England
ID NLM: 100968535
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
received:
15
12
2023
accepted:
01
07
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
11
7
2024
Statut:
epublish
Résumé
Remimazolam is a relatively new benzodiazepine with growing use in procedural sedation and general anaesthesia. Initiated by case reports, the physical incompatibility of remimazolam with ringer's acetated and ringer's lactated solution has been reported. More recently, remifentanil, fentanyl, rocuronium, vecuronium, dexmedetomidine, and midazolam, have been investigated and suggested safe for coadministration with remimazolam. Apart from case reports, incompatibility for other frequently used drugs remains unknown. Sixty-five drugs and intravenous fluids were tested for possible precipitation with remimazolam in a simulated y-site administration. Equal volumes of the test drug were injected into the remimazolam solution, examined and photo documented at 1, 15, 30 and 60 min after mixture. Examination was taken by two independent investigators. pH was measured before, and 60 min after mixing the drugs. Seventeen (26.15%) drugs or fluids showed precipitation, 47 (72.31%) did not show any sign of interaction. Propofol could not be assessed, because of the turbidity of the substance itself. Precipitation occurred immediately and remained stable in all timestamps. The incompatible drug-remimazolam-mixtures had a median pH of 7.15 (6.67, 8.01), the non-precipitating mixtures a median pH of 4.75 (3.8, 5.6). The pH-values of both groups were significantly different (Mann-Whitney-U-test; p < .00001). There is an increasing risk for precipitation with more basic baseline pH-levels of the tested drug. No interaction was seen in baseline pH below 5. Remimazolam (Byfavo
Sections du résumé
BACKGROUND
BACKGROUND
Remimazolam is a relatively new benzodiazepine with growing use in procedural sedation and general anaesthesia. Initiated by case reports, the physical incompatibility of remimazolam with ringer's acetated and ringer's lactated solution has been reported. More recently, remifentanil, fentanyl, rocuronium, vecuronium, dexmedetomidine, and midazolam, have been investigated and suggested safe for coadministration with remimazolam. Apart from case reports, incompatibility for other frequently used drugs remains unknown.
METHODS
METHODS
Sixty-five drugs and intravenous fluids were tested for possible precipitation with remimazolam in a simulated y-site administration. Equal volumes of the test drug were injected into the remimazolam solution, examined and photo documented at 1, 15, 30 and 60 min after mixture. Examination was taken by two independent investigators. pH was measured before, and 60 min after mixing the drugs.
RESULTS
RESULTS
Seventeen (26.15%) drugs or fluids showed precipitation, 47 (72.31%) did not show any sign of interaction. Propofol could not be assessed, because of the turbidity of the substance itself. Precipitation occurred immediately and remained stable in all timestamps. The incompatible drug-remimazolam-mixtures had a median pH of 7.15 (6.67, 8.01), the non-precipitating mixtures a median pH of 4.75 (3.8, 5.6). The pH-values of both groups were significantly different (Mann-Whitney-U-test; p < .00001). There is an increasing risk for precipitation with more basic baseline pH-levels of the tested drug. No interaction was seen in baseline pH below 5.
CONCLUSIONS
CONCLUSIONS
Remimazolam (Byfavo
Identifiants
pubmed: 38992570
doi: 10.1186/s12871-024-02613-7
pii: 10.1186/s12871-024-02613-7
doi:
Substances chimiques
remimazolam
7V4A8U16MB
Benzodiazepines
12794-10-4
Hypnotics and Sedatives
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
233Informations de copyright
© 2024. The Author(s).
Références
Kilpatrick GJ, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107(1):60–6.
doi: 10.1097/01.anes.0000267503.85085.c0
pubmed: 17585216
AG P. PAION web page. 2023 [cited 2023 13.04.2023]; https://www.paion.com/de/produkte/remimazolam/leitsubstanz-remimazolam .
Kilpatrick GJ. Remimazolam: Non-clinical and Clinical Profile of a New Sedative/Anesthetic Agent. Front Pharmacol. 2021;12:690875.
doi: 10.3389/fphar.2021.690875
pubmed: 34354587
pmcid: 8329483
Antonik LJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274–83.
doi: 10.1213/ANE.0b013e31823f0c28
pubmed: 22190555
Worthington MT, et al. A phase ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117(5):1093–100.
doi: 10.1213/ANE.0b013e3182a705ae
pubmed: 24108261
Wiltshire HR, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115(2):284–96.
doi: 10.1213/ANE.0b013e318241f68a
pubmed: 22253270
AG P, ANNEX I SUMMARY OF PRODUCT, CHARACTERISTICS. 2021 [cited 2023 13.04.2023]; https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_en.pdf .
Sneyd JR, Rigby-Jones AE. Remimazolam for anaesthesia or sedation. Curr Opin Anaesthesiol. 2020;33(4):506–11.
doi: 10.1097/ACO.0000000000000877
pubmed: 32530890
Sasaki H, Hoshijima H, Mizuta K. Ringer’s acetate solution-induced precipitation of remimazolam. Br J Anaesth. 2021;126(3):e87–9.
doi: 10.1016/j.bja.2020.11.021
pubmed: 33358048
Sung JM, Kim KN, Jun YE. Precipitation of remimazolam in coadministration with plasma-lyte 148: two case reports. Braz J Anesthesiol. 2023;73(2):234–5.
pubmed: 36377058
Khan S, Stannard N, Greijn J. Precipitation of thiopental with muscle relaxants: a potential hazard. JRSM Short Rep. 2011;2(7):58.
doi: 10.1258/shorts.2011.011031
pubmed: 21847440
pmcid: 3147238
Foinard A, et al. Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility. Ann Intensive Care. 2012;2(1):28.
doi: 10.1186/2110-5820-2-28
pubmed: 22794308
pmcid: 3407719
Mena M. A., Evaluation of strategies for reducing Vancomycin-Piperacillin/Tazobactam incompatibility. Pharmaceutics, 2023. 15(8).
Alston TA. Precipitation of sugammadex by protamine. J Clin Anesth. 2011;23(7):593.
doi: 10.1016/j.jclinane.2011.04.004
pubmed: 22050813
Eckle VS, Grasshoff C. [Precipitation of piritramide and cefazolin. Study of the dependence on concentration and pH] Anaesthesist, 2013. 62(11): pp. 898–901.
Werzer C, Schäfer S, Hofmann-Kiefer K. [Drug interaction between ceftriaxone and theodrenaline/cafedrine: A case example] Anaesthesiologie, 2023. 72(2): pp. 109–112.
Kondo M et al. Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health Syst Pharm, 2022.
Garcia JH, et al. In(compatibility) of intravenous drugs in critical units: adult cohort. Rev Bras Enferm. 2021;74(2):e20200501.
doi: 10.1590/0034-7167-2020-0501
pubmed: 34076220
Nilsson N, et al. Co-administration of intravenous drugs: rapidly troubleshooting the solid form composition of a Precipitate in a multi-drug mixture using On-Site Raman Spectroscopy. Mol Pharm. 2023;20(6):2853–63.
doi: 10.1021/acs.molpharmaceut.2c00983
pubmed: 37167030
pmcid: 10245374
Newton DW. Drug incompatibility chemistry. Am J Health Syst Pharm. 2009;66(4):348–57.
doi: 10.2146/ajhp080059
pubmed: 19202044
Stangroom J. Mann-Whitney U Test Calculator. 2023 [cited 2023 13.04.2023]; https://www.socscistatistics.com/tests/mannwhitney/default.aspx .
Rao SM, Nagendranath V. ARTERIAL BLOOD GAS MONITORING. Indian J Anaesth. 2002;46(4):289–97.